Medical therapy of acromegaly: efficacy and safety of somatostatin analogues (Q37620337)

21 August 2017

1 reference

title

Medical therapy of acromegaly: efficacy and safety of somatostatin analogues (English)

1 reference

21 August 2017

6

Wouter W de Herder

1 reference

21 August 2017

7

Aart-Jan van der Lely

1 reference

Sebastian J C M M Neggers

21 August 2017

4

object named as

Sebastian J Neggers

1 reference

21 August 2017

Richard A Feelders

1

1 reference

21 August 2017

Leo J Hofland

2

1 reference

21 August 2017

Maarten O van Aken

3

1 reference

21 August 2017

Steven W J Lamberts

5

1 reference

21 August 2017

1 November 2009

1 reference

21 August 2017

1 reference

21 August 2017

69

1 reference

21 August 2017

16

1 reference

21 August 2017

2207-2226

1 reference

https://scigraph.springernature.com/pub.10.2165/11318510-000000000-00000

21 August 2017

0 references

cites work

Effects of cortistatin-14 and somatostatin-14 on the endocrine response to hexarelin in humans

1 reference

https://api.crossref.org/works/10.2165%2F11318510-000000000-00000

Efficacy of a slow-release formulation of lanreotide (Autogel) 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11318510-000000000-00000

A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11318510-000000000-00000

The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11318510-000000000-00000

Diagnosis and treatment of acromegaly complications.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11318510-000000000-00000

Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly

21 January 2018

1 reference

12 December 2020

Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors

1 reference

12 December 2020

Consensus statement: medical management of acromegaly

1 reference

12 December 2020

Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly.

1 reference

12 December 2020

Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly

1 reference

12 December 2020

Gender and age in the biochemical assessment of cure of acromegaly

1 reference

12 December 2020

Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs.

1 reference

12 December 2020

A prospective analysis of 151 cases of patients with acromegaly operated by one neurosurgeon: a follow-up of more than 23 years.

1 reference

12 December 2020

Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist

1 reference

12 December 2020

Sandostatin LAR in acromegaly: a 6-week injection interval suppresses GH secretion as effectively as a 4-week interval

1 reference

12 December 2020

Antiangiogenic effects of somatostatin analogues

1 reference

12 December 2020

Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours.

1 reference

12 December 2020

Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial

1 reference

12 December 2020

Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR.

1 reference

12 December 2020

A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly

1 reference

12 December 2020

Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly

1 reference

12 December 2020

Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas

1 reference

12 December 2020

Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage.

1 reference

12 December 2020

Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly.

1 reference

12 December 2020

Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly

1 reference

12 December 2020

Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria

1 reference

12 December 2020

Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly

1 reference

12 December 2020

Cell-specific processing of preprosomatostatin in cultured neuroendocrine cells

1 reference

12 December 2020

Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist

1 reference

12 December 2020

The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status

1 reference

12 December 2020

SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs

1 reference

12 December 2020

Antiproliferative effects of somatostatin analogs in pituitary adenomas

1 reference

12 December 2020

Presurgical treatment with somatostatin analogs in patients with acromegaly: effects on the remission and complication rates

1 reference

12 December 2020

The influence of treatment with somatostatin analogues on morphology, proliferative and apoptotic activity in GH-secreting pituitary adenomas

1 reference

12 December 2020

Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs.

1 reference

12 December 2020

Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa.

1 reference

12 December 2020

Octreotide long-acting release (LAR): a review of its use in the management of acromegaly

1 reference

12 December 2020

Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant.

1 reference

12 December 2020

Somatostatin receptor subtype 1 selective activation in human growth hormone (GH)- and prolactin (PRL)-secreting pituitary adenomas: effects on cell viability, GH, and PRL secretion

1 reference

12 December 2020

The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LAR.

1 reference

12 December 2020

Long-acting somatostatin analog therapy of acromegaly: a meta-analysis

1 reference

12 December 2020

Results of surgical and somatostatin analog therapies and their combination in acromegaly: a retrospective analysis of the German Acromegaly Register

1 reference

12 December 2020

Current concepts in the biochemical assessment of the patient with acromegaly

1 reference

12 December 2020

Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient

1 reference

12 December 2020

Constitutive somatostatin receptor activity determines tonic pituitary cell response.

1 reference

12 December 2020

Perioperative management of patients undergoing transsphenoidal pituitary surgery

1 reference

12 December 2020

Transsphenoidal microsurgery for newly diagnosed acromegaly: a personal view after more than 1,000 operations

1 reference

12 December 2020

Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly

1 reference

12 December 2020

Inhibition of experimental angiogenesis by the somatostatin analogue octreotide acetate (SMS 201-995).

1 reference

12 December 2020

Somatostatin analogs in acromegaly

1 reference

12 December 2020

Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?

1 reference

12 December 2020

Pasireotide (SOM230): development, mechanism of action and potential applications

1 reference

12 December 2020

Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study

1 reference

12 December 2020

Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient

1 reference

12 December 2020

Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy.

1 reference

12 December 2020

Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results

1 reference

12 December 2020

Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide

1 reference

12 December 2020

Quantitative analysis of somatostatin receptor subtype (SSTR1–5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas

1 reference

12 December 2020

Anesthetic and critical care management of patients undergoing pituitary surgery

1 reference

12 December 2020

Four-year follow-up of acromegalic patients treated with the new long-acting formulation of Lanreotide (Lanreotide Autogel).

1 reference

12 December 2020

The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly

1 reference

12 December 2020

Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles

1 reference

12 December 2020

Effects of the long-acting somatostatin analogue Lanreotide Autogel on glucose tolerance and insulin resistance in acromegaly.

1 reference

12 December 2020

Markers of cell proliferation in a GH-producing adenoma of a patient treated with pegvisomant.

1 reference

12 December 2020

Primary therapy for acromegaly with somatostatin analogs and a discussion of novel peptide analogs

1 reference

12 December 2020

Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly

1 reference

12 December 2020

Diagnosis and treatment of acromegaly and its complications: consensus guidelines.

1 reference

12 December 2020

Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly

1 reference

12 December 2020

Epidemiology of acromegaly in the Newcastle region.

1 reference

12 December 2020

A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly

1 reference

12 December 2020

Preoperative lanreotide treatment for GH-secreting pituitary adenomas: effect on tumour volume and predictive factors of significant tumour shrinkage

1 reference

12 December 2020

Insulin regulation of human hepatic growth hormone receptors: divergent effects on biosynthesis and surface translocation

1 reference

12 December 2020

BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide

1 reference

12 December 2020

Effects of octreotide treatment on the proliferation and apoptotic index of GH-secreting pituitary adenomas

1 reference

12 December 2020

Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm

1 reference

12 December 2020

Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes

1 reference

12 December 2020

Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs.

1 reference

12 December 2020

Desensitization and resensitization of rat pituitary tumor cells in long-term culture to the effects of the somatostatin analogue SMS 201-995 on cell growth and prolactin secretion.

1 reference

12 December 2020

Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage.

1 reference

12 December 2020

Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells.

1 reference

12 December 2020

A comparison of octreotide, bromocriptine, or a combination of both drugs in acromegaly

1 reference

12 December 2020

Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly

1 reference

12 December 2020

Antiproliferative effect of the somatostatin analogue octreotide on growth hormone-producing pituitary tumors: results of a multicenter randomized trial

1 reference

12 December 2020

Somatostatin receptors in human growth hormone and prolactin-secreting pituitary adenomas

1 reference

12 December 2020

Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly

1 reference

12 December 2020

Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro.

1 reference

12 December 2020

Criteria for cure of acromegaly: a consensus statement

1 reference

12 December 2020

Acromegaly consensus: the next steps

1 reference

12 December 2020

How effective are current therapies for acromegaly?

1 reference

12 December 2020

Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre

1 reference

12 December 2020

Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients

1 reference

12 December 2020

Mapping of somatostatin receptor types in GH or/and PRL producing pituitary adenomas

1 reference

12 December 2020

High Density of Somatostatin Receptors in Pituitary Tumors from Acromegalic Patients

1 reference

12 December 2020

Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide

1 reference

12 December 2020

Guidelines for acromegaly management

1 reference

12 December 2020

The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro

1 reference

12 December 2020

Octreotide treatment of acromegaly. A randomized, multicenter study

1 reference

12 December 2020

Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial

1 reference

12 December 2020

Octreotide promotes apoptosis in human somatotroph tumor cells by activating somatostatin receptor type 2.

1 reference

12 December 2020

Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients

1 reference

12 December 2020

Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity

1 reference

12 December 2020

Somatostatin and its receptor family

1 reference

12 December 2020

Sandostatin LAR (microencapsulated octreotide acetate) in acromegaly: pharmacokinetic and pharmacodynamic relationships

1 reference

12 December 2020

Cortistatin-17 and -14 exert the same endocrine activities as somatostatin in humans

1 reference

12 December 2020

Presurgical octreotide treatment in acromegaly

1 reference

12 December 2020

Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up

1 reference

12 December 2020

Somatostatin receptor subtype gene expression in pituitary adenomas

1 reference

12 December 2020

Endocrine activities of cortistatin-14 and its interaction with GHRH and ghrelin in humans

1 reference

12 December 2020

Octreotide as primary therapy for acromegaly.

1 reference

12 December 2020

Efficacy of Sandostatin LAR (long-acting somatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and/or radiotherapy

1 reference

12 December 2020

Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly

1 reference

12 December 2020

Pharmacokinetic drug interactions with cyclosporin (Part I).

1 reference

12 December 2020

Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size

1 reference

12 December 2020

Functional association of somatostatin receptor subtypes 2 and 5 in inhibiting human growth hormone secretion.

1 reference

12 December 2020

First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial

1 reference

12 December 2020

Efficacy and safety of the new 60-mg formulation of the long-acting somatostatin analog lanreotide in the treatment of acromegaly

1 reference

12 December 2020

Expression of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumors

1 reference

12 December 2020

Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment.

1 reference

12 December 2020

Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone

1 reference

12 December 2020

Octreotide LAR treatment throughout pregnancy in an acromegalic woman

1 reference

12 December 2020

1 reference

12 December 2020

Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients.

1 reference

12 December 2020

Pharmacokinetic profile of the somatostatin analogue lanreotide in individuals with chronic hepatic insufficiency

1 reference

12 December 2020

Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation

1 reference

12 December 2020

Neuroendocrine tumors secreting growth hormone-releasing hormone: Pathophysiological and clinical aspects

1 reference

12 December 2020

Expression of the five somatostatin receptor (SSTR1-5) subtypes in rat pituitary somatotrophes: quantitative analysis by double-layer immunofluorescence confocal microscopy

1 reference

12 December 2020

Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results?

1 reference

12 December 2020

A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly

1 reference

12 December 2020

Medical progress: Acromegaly

1 reference

12 December 2020

A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients

1 reference

12 December 2020

Somatostatin receptor subtype gene expression in pituitary adenomas

1 reference

12 December 2020

10.2165/11318510-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

21 August 2017

0 references

1 reference